aod9604 pills AOD-9604 500mcg Capsules (60 Count)

In some in-vitro studies, fibroblast cultures exposed to AHK-Cu complexes appeared to show an increase in collagen type I production, with reports of increases as high as 300% over controls

While results are preliminary and limited to experimental systems, the findings highlight possible pathways through which AHK-Cu may interact with cellular processes

The standard research protocol is 300 mcg per day, subcutaneous, administered in a fasted state, typically in the morning before food or exercise

Protective style maintenance

Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption

Area of Interest